MA29570B1 - Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorps - Google Patents
Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorpsInfo
- Publication number
- MA29570B1 MA29570B1 MA30523A MA30523A MA29570B1 MA 29570 B1 MA29570 B1 MA 29570B1 MA 30523 A MA30523 A MA 30523A MA 30523 A MA30523 A MA 30523A MA 29570 B1 MA29570 B1 MA 29570B1
- Authority
- MA
- Morocco
- Prior art keywords
- brain tumors
- antibodies
- treatment
- patient
- monoclonal antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention porte sur une méthode de traitement des tumeurs du cerveau d'un patient par administration systémique d'un anticorps monoclonal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68711805P | 2005-06-02 | 2005-06-02 | |
US75109205P | 2005-12-15 | 2005-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29570B1 true MA29570B1 (fr) | 2008-06-02 |
Family
ID=37482322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30523A MA29570B1 (fr) | 2005-06-02 | 2007-12-27 | Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorps |
Country Status (14)
Country | Link |
---|---|
US (2) | US20070036797A1 (fr) |
EP (1) | EP1885400A4 (fr) |
JP (2) | JP2008545753A (fr) |
KR (1) | KR20080026562A (fr) |
AU (1) | AU2006252419B2 (fr) |
BR (1) | BRPI0611009A2 (fr) |
CA (1) | CA2607699A1 (fr) |
CR (1) | CR9512A (fr) |
IL (1) | IL187318A0 (fr) |
MA (1) | MA29570B1 (fr) |
MX (1) | MX2007015056A (fr) |
NO (1) | NO20080012L (fr) |
RU (1) | RU2007146986A (fr) |
WO (1) | WO2006130773A2 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040208876A1 (en) | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
AU2007254942B2 (en) | 2006-06-02 | 2011-10-27 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
AU2007254853B2 (en) | 2006-06-02 | 2011-11-17 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
EP2066694B1 (fr) | 2006-09-29 | 2015-11-04 | Oncomed Pharmaceuticals, Inc. | Compositions et procédés permettant de diagnostiquer et de traiter le cancer |
US20100150950A1 (en) * | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
EA201000337A1 (ru) * | 2007-08-24 | 2010-10-29 | Новартис Аг | Модулятор nrg1 для лечения респираторных расстройств |
WO2009126840A1 (fr) * | 2008-04-11 | 2009-10-15 | Galaxy Biotech, Llc | Combinaison d’un inhibiteur d’hgf et d’un inhibiteur d’hedgehog pour le traitement du cancer |
PE20091714A1 (es) * | 2008-04-11 | 2009-11-15 | Galaxy Biotech Llc | Combinacion del inhibidor hgf y el agonista pten |
CN102046803B (zh) * | 2008-05-29 | 2014-09-17 | 星系生物科技责任有限公司 | 碱性成纤维细胞生长因子的单克隆抗体 |
US20120052064A1 (en) | 2009-04-17 | 2012-03-01 | Yuuki Ito | Anti-hgf antibody combinational cancer therapies |
ES2700450T3 (es) | 2009-10-16 | 2019-02-15 | Oncomed Pharm Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores |
CN102892779B (zh) * | 2010-02-18 | 2016-12-21 | 基因泰克公司 | 神经调节蛋白拮抗剂及其在治疗癌症中的用途 |
WO2012003338A1 (fr) * | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
US9783602B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
KR102091293B1 (ko) | 2011-09-23 | 2020-03-20 | 온코메드 파마슈티칼스, 인크. | Vegf/dll4 결합제 및 그의 용도 |
WO2014071018A1 (fr) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Méthodes et surveillance d'un traitement par un antagoniste de dll4 |
EP3212233B1 (fr) | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Thérapie combinée pour le traitement d'une maladie |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2564486B2 (ja) * | 1986-07-14 | 1996-12-18 | 修治 橋本 | 肝細胞増殖因子 |
US6498144B1 (en) * | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
US5837676A (en) * | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
US5707624A (en) * | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
US5646036A (en) * | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
ATE465257T1 (de) * | 1996-07-03 | 2010-05-15 | Genentech Inc | Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen |
WO2004019991A2 (fr) * | 2002-08-30 | 2004-03-11 | F. Hoffmann-La Roche Ag | Antagoniste nk4 du facteur de croissance de l'hepatocyte/du facteur de dispersion pour le traitement de gliome |
US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
US7220410B2 (en) * | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
TWI476206B (zh) * | 2003-07-18 | 2015-03-11 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
ATE517091T1 (de) * | 2003-09-26 | 2011-08-15 | Exelixis Inc | C-met-modulatoren und verwendungsverfahren |
EP1773826A4 (fr) * | 2004-07-02 | 2009-06-03 | Exelixis Inc | Modulateurs de c-met et leur methode d'utilisation |
WO2007056523A2 (fr) * | 2005-11-08 | 2007-05-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Procedes de diagnostic et de surveillance de la progression d'un cancer |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
WO2009126840A1 (fr) * | 2008-04-11 | 2009-10-15 | Galaxy Biotech, Llc | Combinaison d’un inhibiteur d’hgf et d’un inhibiteur d’hedgehog pour le traitement du cancer |
TW201002346A (en) * | 2008-04-11 | 2010-01-16 | Galaxy Biotech Llc | Combination of HGF inhibitor and EGF inhibitor to treat cancer |
-
2006
- 2006-06-01 US US11/446,045 patent/US20070036797A1/en not_active Abandoned
- 2006-06-01 MX MX2007015056A patent/MX2007015056A/es not_active Application Discontinuation
- 2006-06-01 EP EP06771847A patent/EP1885400A4/fr not_active Withdrawn
- 2006-06-01 JP JP2008514858A patent/JP2008545753A/ja active Pending
- 2006-06-01 BR BRPI0611009-6A patent/BRPI0611009A2/pt not_active IP Right Cessation
- 2006-06-01 AU AU2006252419A patent/AU2006252419B2/en not_active Ceased
- 2006-06-01 RU RU2007146986/14A patent/RU2007146986A/ru not_active Application Discontinuation
- 2006-06-01 WO PCT/US2006/021293 patent/WO2006130773A2/fr active Application Filing
- 2006-06-01 KR KR1020077030521A patent/KR20080026562A/ko not_active Application Discontinuation
- 2006-06-01 CA CA002607699A patent/CA2607699A1/fr not_active Abandoned
-
2007
- 2007-11-12 CR CR9512A patent/CR9512A/es not_active Application Discontinuation
- 2007-11-12 IL IL187318A patent/IL187318A0/en unknown
- 2007-12-27 MA MA30523A patent/MA29570B1/fr unknown
-
2008
- 2008-01-02 NO NO20080012A patent/NO20080012L/no not_active Application Discontinuation
-
2010
- 2010-01-19 US US12/690,045 patent/US20100221250A1/en not_active Abandoned
-
2013
- 2013-01-10 JP JP2013002317A patent/JP2013136580A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2007015056A (es) | 2008-03-11 |
KR20080026562A (ko) | 2008-03-25 |
CA2607699A1 (fr) | 2006-12-07 |
JP2013136580A (ja) | 2013-07-11 |
US20070036797A1 (en) | 2007-02-15 |
US20100221250A1 (en) | 2010-09-02 |
JP2008545753A (ja) | 2008-12-18 |
CR9512A (es) | 2008-04-16 |
BRPI0611009A2 (pt) | 2010-08-10 |
EP1885400A2 (fr) | 2008-02-13 |
IL187318A0 (en) | 2008-04-13 |
WO2006130773A3 (fr) | 2009-04-16 |
WO2006130773A2 (fr) | 2006-12-07 |
AU2006252419A1 (en) | 2006-12-07 |
AU2006252419B2 (en) | 2012-02-02 |
RU2007146986A (ru) | 2009-06-27 |
EP1885400A4 (fr) | 2011-01-26 |
NO20080012L (no) | 2008-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29570B1 (fr) | Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorps | |
LUC00053I9 (fr) | Anticorps diriges contre cd38 pour le traitement du myelome multiple | |
MX2018000505A (es) | Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos. | |
MA30337B1 (fr) | Anticorps | |
MA47313A (fr) | Formulations sous-cutanées d'anticorps her2 | |
MA51669B1 (fr) | Modulateurs de tmem16a | |
CR7922A (es) | Inmunizacion activa para generar anticuerpos para beta-a- soluble | |
MA34647B1 (fr) | Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17 | |
DE60042693D1 (de) | Dosierung für die behandlung mit anti erbb2-antikörpern | |
MA33122B1 (fr) | Molecules d'anticorps ayant une specificite pour ox40 humain | |
MA31886B1 (fr) | Anticorps anti-hepcidine et utilisations de ceux-ci | |
MA30876B1 (fr) | Anticorps de la lymphotoxine-alpha | |
MX2008012023A (es) | Metodos para prevenir y tratar enfermedades amiloidogenicas. | |
TW200728466A (en) | Antibody molecules having specificity for human IL-6 | |
EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
DE60226051D1 (de) | Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren | |
MA37946B1 (fr) | Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde | |
MA35173B1 (fr) | Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer | |
MX2021011715A (es) | Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención. | |
MA38161A1 (fr) | Anticorps anti-bmp-6 | |
DK1641828T3 (da) | Anti-HGF-R-antistoffer og deres anvendelse | |
MA53765A1 (fr) | Tubulysines et conjugués tubulysines-protéines | |
FR2904248B1 (fr) | Procede de traitement bio-assiste d'un sol contamine par des hydrocarbures. | |
MA37670A1 (fr) | Anticorps anti-transglutaminase 2 | |
MA27592A1 (fr) | Agonistes du recepteur du facteur de liberation 2 de la corticotropine. |